IM8N Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
BRINSUPRI Launch ExecutionBRINSUPRI is showing rapid commercial adoption, expanding prescriber breadth and strong patient starts. The raised revenue outlook indicates meaningful near-term scale, while increasing repeat prescribing can support a durable growth platform as market awareness and utilization deepen.
Pipeline Strength And TPIP ProgressPositive TPIP durability and safety data strengthen Insmed’s pipeline beyond its current products. Progress toward Phase 3 increases the potential for a differentiated future therapy, broadening the company’s growth base and supporting longer-term commercial diversification.
Improved Balance Sheet And Funding RunwayMaterial debt reduction and positive equity improve financial flexibility, while the cash balance provides resources for launches and late-stage trials. Management’s stated expectation of cash-flow positivity in 2027 without new capital further supports near-term funding sustainability.
Bears Say
Heavy Cash Burn And Ongoing LossesInsmed remains reliant on substantial cash resources while its commercial portfolio and pipeline investments have not yet produced profitability. Persistent operating and free-cash-flow deficits can reduce financial flexibility and increase execution pressure before the projected 2027 inflection.
High Investment RequirementsSupporting multiple launches and Phase III programs requires significant ongoing spending, limiting operating leverage even as revenue grows. Additional commercial and development investment could prolong losses and cash consumption, making profitability dependent on successful execution across several programs.
Reimbursement And Net-revenue PressureEuropean reimbursement constraints may reduce international revenue upside, while rising gross-to-net deductions can weaken the conversion of reported demand into net sales. Together, these pressures could limit margins and make future growth more dependent on U.S. execution and product expansion.
Insmed News
IM8N FAQ
What was Insmed’s price range in the past 12 months?
Currently, no data Available
What is Insmed’s market cap?
Insmed’s market cap is CHF21.31B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Oct 22, 2026 which is in 25 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Aug 06, 2026. The company reported -CHF0.05 earnings per share for the quarter, beating the consensus estimate of -CHF0.555 by CHF0.505.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.32.
How many shares outstanding does Insmed have?
Insmed has 218,381,500 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -CHF0.05 in its last earnings report, beating expectations of -CHF0.555. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in CH:IM8N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF165.45 (― Upside)
CHF165.45 (― Upside)
Blogger Sentiment
Bullish
CH:IM8N Sentiment 73%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF29.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
IM8N Company Deck
IM8N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial execution and materially improved financial and clinical momentum — highlighted by BRINSUPRI’s historic launch ($309.2M Q2, raised FY guidance to $1.25B–$1.4B, peak >$7B), solid ARIKAYCE performance ($116.3M, +8% YoY) and compelling TPIP clinical data with upgraded peak potential (> $6B). Management emphasized a healthy cash position (~$1.2B) and a clear path to cash-flow positivity in 2027. Offsetting risks include higher near-term operating spend (R&D and SG&A +38% YoY), European reimbursement headwinds, milestone payments (~$50M H2 2026), and reliance on optimistic assumptions (diagnosis expansion, regulatory success, pricing). Overall, the positive commercial results, clinical readouts and funding runway substantially outweigh the noted operational and market uncertainties.View all CH:IM8N earnings summariesIM8N Stock 12 Month Forecast
Average Price Target
―Alnylam Pharma
―
BioMarin Pharmaceutical
―
United Therapeutics
―
Ultragenyx Pharmaceutical
―
Avalyn Pharma Inc
―